EP4069244A4 - Verwendung von reboxetin zur behandlung von störungen des nervensystems - Google Patents
Verwendung von reboxetin zur behandlung von störungen des nervensystems Download PDFInfo
- Publication number
- EP4069244A4 EP4069244A4 EP20895126.9A EP20895126A EP4069244A4 EP 4069244 A4 EP4069244 A4 EP 4069244A4 EP 20895126 A EP20895126 A EP 20895126A EP 4069244 A4 EP4069244 A4 EP 4069244A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- reboxetine
- nervous system
- system disorders
- treat nervous
- treat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000012902 Nervous system disease Diseases 0.000 title 1
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 title 1
- 229960003770 reboxetine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962943077P | 2019-12-03 | 2019-12-03 | |
| US201962946295P | 2019-12-10 | 2019-12-10 | |
| US16/740,329 US20200147093A1 (en) | 2018-10-15 | 2020-01-10 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| US16/740,409 US11351175B2 (en) | 2018-10-15 | 2020-01-11 | Use of reboxetine to treat narcolepsy |
| US16/740,411 US20200147096A1 (en) | 2018-10-15 | 2020-01-11 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| US16/740,410 US20200147095A1 (en) | 2018-10-15 | 2020-01-11 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| PCT/US2020/062560 WO2021113163A1 (en) | 2019-12-03 | 2020-11-30 | Use of reboxetine to treat nervous system disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4069244A1 EP4069244A1 (de) | 2022-10-12 |
| EP4069244A4 true EP4069244A4 (de) | 2023-12-20 |
Family
ID=81851750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20895126.9A Pending EP4069244A4 (de) | 2019-12-03 | 2020-11-30 | Verwendung von reboxetin zur behandlung von störungen des nervensystems |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4069244A4 (de) |
| JP (1) | JP2023504685A (de) |
| KR (1) | KR20220108122A (de) |
| CN (1) | CN114746097A (de) |
| AU (1) | AU2020395082A1 (de) |
| BR (1) | BR112022010677A2 (de) |
| CA (1) | CA3163505A1 (de) |
| CO (1) | CO2022007507A2 (de) |
| CR (1) | CR20220247A (de) |
| IL (1) | IL293536A (de) |
| MX (1) | MX2022006630A (de) |
| PE (1) | PE20230181A1 (de) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL197985B1 (pl) * | 1999-07-01 | 2008-05-30 | Upjohn Co | Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku |
| ES2246485T3 (es) * | 1999-07-01 | 2006-02-16 | PHARMACIA & UPJOHN COMPANY LLC | (s,s)-reboxetina para tratar la incontinencia. |
| WO2008137923A2 (en) * | 2007-05-07 | 2008-11-13 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders |
| SI2968208T1 (sl) * | 2013-03-13 | 2023-02-28 | Jazz Pharmaceuticals Ireland Limited, | Zdravljenje katapleksije |
-
2020
- 2020-11-30 CN CN202080083484.4A patent/CN114746097A/zh active Pending
- 2020-11-30 AU AU2020395082A patent/AU2020395082A1/en not_active Abandoned
- 2020-11-30 KR KR1020227022167A patent/KR20220108122A/ko unknown
- 2020-11-30 JP JP2022533248A patent/JP2023504685A/ja active Pending
- 2020-11-30 IL IL293536A patent/IL293536A/en unknown
- 2020-11-30 CA CA3163505A patent/CA3163505A1/en active Pending
- 2020-11-30 BR BR112022010677A patent/BR112022010677A2/pt unknown
- 2020-11-30 PE PE2022000980A patent/PE20230181A1/es unknown
- 2020-11-30 MX MX2022006630A patent/MX2022006630A/es unknown
- 2020-11-30 EP EP20895126.9A patent/EP4069244A4/de active Pending
- 2020-11-30 CR CR20220247A patent/CR20220247A/es unknown
-
2022
- 2022-05-31 CO CONC2022/0007507A patent/CO2022007507A2/es unknown
Non-Patent Citations (4)
| Title |
|---|
| GARCIA-BORREGUERO D ET AL: "567.K Effects of reboxetine in narcolepsy-cataplexy: Preliminary findings on 14 patients", SLEEP; 15TH ANNUAL MEETING OF THE ASSOCIATED PROFESSIONAL SLEEP SOCIETIES; CHICAGO, ILLINOIS, USA; JUNE 05-10, 2001, ALLEN PRESS, LAWRENCE, KS, US, vol. 24, no. Abstract Supplement, 15 April 2001 (2001-04-15), pages A323 - A324, XP009531711, ISSN: 0161-8105 * |
| O' GORMAN CEDRIC ET AL: "SCIENTIFIC RATIONALE AND CLINICAL DEVELOPMENT OF AXS-12 FOR NARCOLEPSY", SLEEP, vol. 42, no. Abstract Supplement, 1 January 2019 (2019-01-01), pages A24, XP055866024 * |
| SCHMIDT CHRISTIAN ET AL: "The norepinephrine reuptake inhibitor reboxetine is more potent in treating murine narcoleptic episodes than the serotonin reuptake inhibitor escitalopram", BEHAVIOURAL BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 308, 23 April 2016 (2016-04-23), pages 205 - 210, XP029542431, ISSN: 0166-4328, DOI: 10.1016/J.BBR.2016.04.033 * |
| See also references of WO2021113163A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022006630A (es) | 2022-06-24 |
| IL293536A (en) | 2022-08-01 |
| AU2020395082A1 (en) | 2022-06-09 |
| EP4069244A1 (de) | 2022-10-12 |
| JP2023504685A (ja) | 2023-02-06 |
| BR112022010677A2 (pt) | 2022-08-16 |
| CN114746097A (zh) | 2022-07-12 |
| CR20220247A (es) | 2022-08-18 |
| PE20230181A1 (es) | 2023-02-01 |
| CA3163505A1 (en) | 2021-06-10 |
| CO2022007507A2 (es) | 2022-06-21 |
| KR20220108122A (ko) | 2022-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4010072A4 (de) | Behandlung von erkrankungen des zentralnervensystems | |
| EP3526319A4 (de) | Verfahren und zusammensetzungen und zur behandlung von erkrankungen und störungen des zentralnervensystems | |
| EP3259017A4 (de) | Nervenstimulierung zur behandlung von erkrankungen und störungen | |
| EP3389725A4 (de) | Zusammensetzungen und verfahren zur behandlung von erkrankungen des zentralen nervensystems | |
| EP3618824A4 (de) | Verwendung von n-acetylcystein zur behandlung von erkrankungen des zentralen nervensystems | |
| EP3596063A4 (de) | Pyrimidinyl-pyridyloxy-naphthylverbindungen und verfahren zur behandlung von ire1-bedingten erkrankungen und störungen | |
| EP3579830A4 (de) | Cannabinoidhaltige fettsäureformulierungen zur behandlung von erkrankungen des nervensystems | |
| EP3507371A4 (de) | Verfahren und zusammensetzungen und zur behandlung von erkrankungen und störungen des nervensystems | |
| EP3700525A4 (de) | Verbesserte bereitstellung von antioxidantien zur behandlung von erkrankungen des zentralen nervensystems mit oxidativem stress | |
| EP3270914A4 (de) | Verbindungen und formen zur behandlung von weiblichen sexuellen störungen | |
| EP3826650A4 (de) | Verfahren zur behandlung von neurologischen erkrankungen | |
| EP3914231A4 (de) | Behandlung von hauterkrankungen mit topischen tapinarof-kombinationszusammensetzungen | |
| CA3082254A1 (en) | Heterocyclic compounds as kinase inhibitors | |
| EP3856169A4 (de) | Verfahren zur behandlung von myeloproliferativen erkrankungen | |
| EP3826649A4 (de) | Verfahren zur behandlung von neurologischen störungen | |
| EP4069847A4 (de) | Behandlung von erkrankungen der unteren atemwege | |
| EP4003299A4 (de) | Behandlung von hauterkrankungen mit topischen tapinarof-egfr-inhibitorzusammensetzungen | |
| IL283503A (en) | Combined treatment of primary central nervous system lymphoma | |
| EP3634370A4 (de) | Behandlung von hautkrankheiten | |
| EP3927428A4 (de) | Verfahren zur behandlung von atemwegserkrankungen | |
| IL274233A (en) | Compounds, preparations and methods for the treatment of eye disorders and skin diseases | |
| EP3911313A4 (de) | Thienyl-anilin-verbindungen zur behandlung von hauterkrankungen | |
| GB201914034D0 (en) | Treatment of neurological disorders | |
| EP3856198A4 (de) | Behandlung von hämatologischen störungen niedriger intensität | |
| EP3866768A4 (de) | Verwendung von reboxetin zur behandlung von narkolepsie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20220628 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40080135 Country of ref document: HK |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230515 |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20231122 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 43/00 20060101ALI20231116BHEP Ipc: A61P 25/00 20060101ALI20231116BHEP Ipc: A61P 25/24 20060101ALI20231116BHEP Ipc: A61K 31/5375 20060101AFI20231116BHEP |